Correction: Proteomic-based stratification of intermediate-risk prostate cancer patients
This study demonstrates the ability of a protein-based signature to risk-stratify prostate cancer patients with Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence.
Authors
- Jan H. Rueschoff
- Guo-Bo Chen
- Niels J. Rupp (ORCID: https://orcid.org/0000-0002-7043-3456)
- Tiansheng Zhu (ORCID: https://orcid.org/0000-0002-7335-9087)
- Zainab Noor (ORCID: https://orcid.org/0000-0002-9314-5705)
- Rebecca C. Poulos (ORCID: https://orcid.org/0000-0002-8419-7028)
- Janis Frederick Neumann
- Asim Anees (ORCID: https://orcid.org/0000-0003-2220-0874)
- P Hains
- Natasha S. Lucas (ORCID: https://orcid.org/0000-0002-1691-913X)
- Dorothea Rutishauser (ORCID: https://orcid.org/0000-0003-2303-103X)
- Adel T. Aref (ORCID: https://orcid.org/0000-0003-3028-131X)
- Andreas Beyer (ORCID: https://orcid.org/0000-0001-9129-7492)
- Thomas Hermanns
- Mengge Lyu
- Roger R Reddel
- Cédric Poyet
- María Alejandra Rodríguez Martínez
- Qing Zhong
- Wenguang Shao
- Phillip J Robinson
- Tiannan Guo
- Yi Zhu
- Marija Buljan
- Yingrui Wang
- Ruedi Aebersold
- Rui Sun
- Christian Fankhauser
- Xuan Ding
- Peter J Wild
Publication Details
- Journal
- Universität Zürich, ZORA
- Published
- 2025-12-01
- DOI
- https://doi.org/10.5167/uzh-291003
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00